Good morning and welcome to Syros Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being ...

Syros Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.72. Operator: Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial ...

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) stock is trading lower on Tuesday after the company issued an update on the SELECT-AML-1 Phase 2 trial. The company announced that it will discontinue ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago. These ...

(RTTNews) - Syros Pharmaceuticals (SYRS) and TYME Technologies, Inc. (TYME) announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, ...

Good morning, and welcome to Syros Pharmaceuticals Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode. This call is being webcast live on the ...

Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate. The trial assessed tamibarotene in ...

Syros Pharmaceuticals Inc received notice from Pfizer Inc PFE, as successor to Global Blood Therapeutics Inc, exercising its right to terminate the License and Collaboration Agreement dated December ...

Operator: Good morning and welcome to Syros Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast ...

Syros Pharmaceuticals, Inc. (SYRS) just came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.52 per share a year ago.